Skip to content

Updates on HERA study?

Page last modified on: August 19, 2008
Question from KathyM: Are there any updates about the 2-year arm of the HERA study? I was in the 2-year study and am very interested, especially around relapse. Thank you.
Answer —Generosa Grana, M.D., F.A.C.P.: There is no data yet available on the HERA group that received 2 years of Herceptin (chemical name: trastuzumab). For the present, the standard remains 1 year of therapy. And we look forward to that data becoming available.

On Wednesday, June 18, 2008 our Ask-the-Expert Online Conference was called Updates from the 2008 ASCO Annual MeetingGenerosa Grana, M.D., F.A.C.P. and Carol Kaplan, M.D. answered your questions about the latest research advances on screening, treatment, side effects, and more.


The materials presented in these conferences do not necessarily reflect the views of breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2008. All rights reserved.

Together we can make a difference

Email Updates

Stay informed about current research, online events, and more.

Please leave this field empty

Meet the Experts

Generosa Grana, M.D., F.A.C.PGenerosa Grana, M.D., F.A.C.P. is the director of the Cooper Cancer Institute and heads the division of hematology/medical oncology at Cooper University Hospital.

Carol Kaplan, M.D. is an assistant professor of clinical medicine in the Rena Rowan Breast Center at the Hospital of the University of Pennsylvania. Her work revolves around the clinical care of breast cancer patients, as well as teaching medical students and house staff.

Back to top

Breastcancer.org 7 East Lancaster Avenue, 3rd Floor Ardmore, PA 19003

Learn more about our commitment to your privacy

© 2010 Breastcancer.org - All rights reserved.

Breastcancer.org is a non-profit organization dedicated to providing information and community to those touched by this disease. Learn more about our commitment to providing complete, accurate, and private breast cancer information.